We believe this approach is particularly meritorious considering the cancer selectivity of sigma-2 ligands and the important contribution of IAPs to both de-novo and acquired treatment resistance, and therefore deserves serious consideration for future clinical development. The gene discussed is AP2S1; the disease is cancer.